Impact1 at Stanford Biodesign

09/13/2023

Our Impact1 team, alongside an amazing group of biodesigners, had the privilege of reconnecting with the Women community during the Vision event. The theme of this year, centered around promoting health equity, deeply aligns with 's core mission of supporting our most vulnerable and underserved populations.

Let's continue this important dialogue as we persist in our efforts to help solutions that address unmet needs in pediatrics and maternal health make a positive impact on patients’ lives.

08/28/2023

Congratulations Earflo for being selected as a finalist for the Western Australia’s Innovator of the Year Award 2023 (WAIOTY)! This prestigious award recognizes the brightest innovators and entrepreneurs who are developing outstanding innovative products, technologies or services that clearly demonstrates an economic, social or environmental benefit.

Earflo is dedicated to the development of a non-invasive at-home device to treat chronic ear infections, sparing pediatric patients from the need of undergoing surgery. Guided by the outstanding leadership of Intan Oldakowsa as CEO, and Matthew Oldakowski as founder and CTO, Earflo is making a real difference in pediatrics! At Impact1 we take great pride in supporting them, and we are glad to follow from close they remarkable progress and impact.

Earflo is set to embark on a forthcoming clinical trial to assess the efficacy of their innovative device for ear infection treatment in Perth. For more information on the trial, you can reach out to: intan.oldakowska@uwa.edu.au

08/25/2023

At Impact1 at Stanford Biodesign, we are excited to back projects and startups making a real difference in pediatric and maternal health. One of the companies that we are proud to support is Eclipse Regenesis. They are currently developing Eclipse XL1, the first tissue regeneration therapy for short bowel syndrome.

Short bowel syndrome is a devastating condition in which patients struggle to absorb sufficient and life-sustaining nutrients as a result thereof intestinal resection. Without a restorative solution available, patients with short bowel syndrome are reliant on life-sustaining solutions such as total parenteral nutrition, drug therapies, and surgical or intestinal transplantation.

Leading the company are some impressive healthcare innovators: Andre Bessette, the CEO and Co-Founder, along with James Dunn, MD, PhD, and Tom Krummel, MD, who are also Co-Founders. They are a robust team set on changing the game in pediatric and maternal health.

You can find more information about the company on their website: https://www.eclipseregenesis.com

08/03/2023

Impact1 is dedicated to advancing pediatric and maternal health technology for a positive impact right from day one. We are thrilled to announce a significant update regarding our leadership team. Janene Fuerch and Kunj Sheth are taking on the roles of co-directors at Impact1, while Juliana Perl and Elisabet Rosàs will serve as assistant directors.

Janene Fuerch, co-director at Impact1, is a Clinical Associate Professor of Neonatology at Stanford University Medical Center. Beyond her medical expertise, she is also an innovator, educator, and researcher. Janene's work centers around enhancing the well-being of women and children through groundbreaking innovation and research.

Kunj Sheth, also a co-director at Impact1, serves as Assistant Professor of Pediatric Urology at Stanford University. Kunj's research is focused on advancing the field by developing cutting-edge biomedical devices. Additionally, Kunj leads the perioperative Value Analysis Committee and the surgical robotics program at Lucile Packard Children’s Hospital.

Finally, in their new roles as assistant directors, Juliana Perl and Elisabet Rosàs-Canyelles remain unwavering in their dedication to the mission of improving the health, safety, and overall quality of life for pediatric patients and expectant mothers.

07/26/2023

Impact1 is dedicated to advancing pediatric, fetal, and maternal health technology to impact lives from day one. In 2022, we were thrilled to support 39 teams of innovators through coaching, connections, funding, and more.

What exactly is Impact1? Formerly known as the Pediatric Health Technology Program at Stanford Byers Center for Biodesign, we work to educate entrepreneurs, conduct translational research, and engage in health policy reform.

07/26/2023

07/26/2023